Several potentially targetable mutations were also identified, including mutations in KRAS and RET. KRAS mutations were detected in one LCC patient (p.G12V) and one LCNEC patient (p.G12C). This evidence concerns the gene KRAS and leukoencephalopathy with calcifications and cysts.